Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Complete Title: Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft vs. Host Disease after Allogeneic Hematopoietic Cell Transplantation
Trial Phase: II
Investigator: Stephanie Lee, MD, MPH
This phase II trial studies how well ustekinumab works in preventing acute graft versus host disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells from a donor can attack the body`s normal tissues (called graft-versus-host disease). Giving ustekinumab after the transplant may help prevent acute graft versus host disease by controlling the body`s immune response.
Keywords:
- Leukemia, Chronic Lymphocytic (CLL)
- Leukemia, Lymphoid
- Lymphoma, Small Lymphocytic (SLL)
- Leukemia, Prolymphocytic
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Large Granular Lymphocytic
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Stephanie Lee, MD, MPH
RG1005588
NCT04572815
Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft vs. Host Disease after Allogeneic Hematopoietic Cell Transplantation
Leukemia, Chronic Lymphocytic (CLL)
Leukemia, Lymphoid
Lymphoma, Small Lymphocytic (SLL)
Leukemia, Prolymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Large Granular Lymphocytic